River Road Asset Management LLC Has $38.97 Million Holdings in Bausch + Lomb Co. (NYSE:BLCO)

River Road Asset Management LLC boosted its stake in Bausch + Lomb Co. (NYSE:BLCO - Free Report) by 4.4% in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 2,020,414 shares of the company's stock after buying an additional 85,987 shares during the quarter. River Road Asset Management LLC owned approximately 0.57% of Bausch + Lomb worth $38,974,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also modified their holdings of BLCO. Whitebox Advisors LLC grew its stake in Bausch + Lomb by 28.2% in the 2nd quarter. Whitebox Advisors LLC now owns 1,545,946 shares of the company's stock valued at $22,447,000 after buying an additional 339,643 shares during the last quarter. Clearline Capital LP boosted its position in shares of Bausch + Lomb by 136.8% during the 2nd quarter. Clearline Capital LP now owns 712,055 shares of the company's stock valued at $10,339,000 after acquiring an additional 411,404 shares in the last quarter. Point72 Europe London LLP boosted its position in shares of Bausch + Lomb by 28.9% during the 2nd quarter. Point72 Europe London LLP now owns 653,492 shares of the company's stock valued at $9,489,000 after acquiring an additional 146,583 shares in the last quarter. Point72 Asset Management L.P. boosted its position in shares of Bausch + Lomb by 31.0% during the 2nd quarter. Point72 Asset Management L.P. now owns 647,156 shares of the company's stock valued at $9,397,000 after acquiring an additional 153,000 shares in the last quarter. Finally, Invenomic Capital Management LP acquired a new stake in shares of Bausch + Lomb during the 1st quarter valued at about $6,817,000. Institutional investors own 11.07% of the company's stock.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on the stock. Royal Bank of Canada lifted their target price on shares of Bausch + Lomb from $20.00 to $23.00 and gave the company an "outperform" rating in a research report on Tuesday, October 22nd. Stifel Nicolaus lifted their price target on shares of Bausch + Lomb from $16.00 to $19.00 and gave the company a "hold" rating in a report on Monday, September 23rd. Raymond James initiated coverage on shares of Bausch + Lomb in a report on Wednesday, July 10th. They set an "outperform" rating and a $19.00 price target for the company. Evercore ISI raised shares of Bausch + Lomb from an "in-line" rating to an "outperform" rating and lifted their price target for the company from $19.00 to $25.00 in a report on Tuesday, October 15th. Finally, HC Wainwright lifted their price target on shares of Bausch + Lomb from $22.00 to $23.00 and gave the company a "buy" rating in a report on Thursday, October 31st. Five equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company's stock. Based on data from MarketBeat.com, Bausch + Lomb currently has an average rating of "Moderate Buy" and a consensus price target of $20.91.

Bausch + Lomb Trading Down 0.3 %

Shares of BLCO traded down $0.06 on Tuesday, reaching $19.81. 776,763 shares of the company's stock were exchanged, compared to its average volume of 572,355. The company has a current ratio of 1.57, a quick ratio of 0.95 and a debt-to-equity ratio of 0.69. The stock has a market capitalization of $6.97 billion, a P/E ratio of -18.87, a price-to-earnings-growth ratio of 1.93 and a beta of 0.46. The business has a 50 day moving average price of $18.68 and a two-hundred day moving average price of $16.52. Bausch + Lomb Co. has a 12 month low of $13.16 and a 12 month high of $21.69.

Bausch + Lomb (NYSE:BLCO - Get Free Report) last posted its quarterly earnings results on Wednesday, October 30th. The company reported $0.17 earnings per share for the quarter, topping analysts' consensus estimates of $0.16 by $0.01. The business had revenue of $1.20 billion during the quarter, compared to the consensus estimate of $1.17 billion. Bausch + Lomb had a negative net margin of 7.86% and a positive return on equity of 3.17%. Bausch + Lomb's revenue for the quarter was up 18.8% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.22 earnings per share. Research analysts anticipate that Bausch + Lomb Co. will post 0.59 earnings per share for the current year.

Bausch + Lomb Profile

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief.